ArticleClinical rheumatology2026
Anti-CD74 IgA as a potential biomarker in axial spondyloarthritis: diagnostic utility and clinical implications.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgA anti-CD74 autoantibodies are associated with treatment escalation in peripheral psoriatic arthritis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxial spondyloarthritis (axSpA) is chronic autoimmune disease affecting axial skeleton. Recently autoantibodies against CD74 have been linked to the pathogenesis of axSpA.
objectivesInvestigate the diagnostic value of anti-CD74 in Egyptian axSpA patients and their relation to disease activity.
methodsThis study included 30 axSpA patients and control groups, which included 30 patients with peripheral psoriatic arthritis, and 30 healthy volunteers. disease activity was assessed using ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score) and BASDAI (bath ankylosing spondylitis disease activity index) for axSpA patients. Bath ankylosing spondylitis functional index (BASFI) was used for functional assessment and mobility was assessed using Bath Ankylosing Spondylitis Metrology Index (BASMI). ESR, CRP and serum anti-CD74 IgA were evaluated.
resultsThere was no significant difference between the three studied groups regarding sex, age, and BMI. The serum levels of anti-CD74 IgA antibodies were significantly higher in axSpA patients compared to control groups.73.3, 66.6 and 3.3% of the axSpA, Peripheral psoriatic arthritis and healthy group, respectively, were anti- CD74 IgA antibody positive. Its specificity was 96.67% compared to the healthy control group, and 33.3% specificity compared to the peripheral psoriatic arthritis group. There was no significant correlation between anti-CD74 IgA antibodies and age, sex, duration of the disease, acute phase reactant, ASDAS-CRP, BASDAI, BASFI, and BASMI.
conclusionsIgA anti-CD74 may be a useful marker for identifying axSpA. Further research on patients with peripheral SpA is required to determine the practical benefits of this biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.